Gilead's statement about the launch of a clinical trial of Redsewe inhalers for outpatient treatment of new coronavirus pneumonia.

Guide: A large number of studies have been carried out on Redsewe inhaled sprays!---- U.Stime on July 8, 2020, Merced Parsey, Global Medical Officer of Gilead Sciences, issued the following statement on behalf of the company: "Since the beginning of the new coronavirus pneumonia pandemic, Gilead has used its deep expertise in virology to rapidly evaluate its effective and effective treatment as a patient with the new coronavirusWith promising data obtained in randomized clinical trials of intravenous Redsiwe in patients, research needs have been identified for the drug's potential for use in outpatient clinicsa large number of research work has been done on Redsiwe's inhaled sprayswe are pleased to announce the launch of a Phase 1a clinical study of Redsewe in the study of inhalant forms to assess its safety, tolerance and pharmacokinetics in healthy volunteersAccording to current scientific understanding, the upper respiratory tract is the site of the most common viral infection of the new coronavirus pneumonia in the early stages of the diseaseuse atomized inhalation of the solution directly to the infection of the primary site, can make non-inpatients more targeted and tactile medication, and may reduce the drug in the body's systemic exposurethis randomized, placebo-controlled trial will recruit about 60 healthy individuals between the ages of 18 and 45 in the United States as a basis for further clinical studies of inhalation drugs, especially for patients whose condition has not yet developed to require hospitalizationresearch into Redsiwelic inhalable solutions is an important direction of our ongoing efforts to improve the efficacy of Redsewe's treatment and to make this treatment available to more patientsmore clinical trialstargeting susceptible groups, medication in outpatient settings, and Redsivir's combination of anti-inflammatory drugs are currently under way or are scheduled to startwe will continue to share new data with regulators, the scientific community and the medical community, working together to help meet the needs of patients around the world"s on Redsey-Riversiwe is a nucleotide analogue that has broad-spectrum antiviral activity both in animals and in vitro and can fight against a variety of emerging viral pathogensseveral ongoing global Phase III clinical trials are evaluating the safety and effectiveness of Redsiwe's treatment of new coronavirus pneumoniaapproval of Redsewee varies from country to countryredseweve is still a drug in the research in countries that have not been approved by local health authorities, and its safety and efficacy have not yet been proven.